-+ 0.00%
-+ 0.00%
-+ 0.00%
12 Health Care Stocks Moving In Thursday's After-Market Session
Share
Listen to the news

Gainers

  • Alaunos Therapeutics (NASDAQ:TCRT) shares moved upwards by 30.0% to $2.08 during Thursday's after-market session. The company's market cap stands at $3.2 million.
  • cbdMD (AMEX:YCBD) stock increased by 13.84% to $0.57. The company's market cap stands at $5.2 million.
  • Telomir Pharmaceuticals (NASDAQ:TELO) stock rose 11.6% to $1.25. The company's market cap stands at $77.7 million.
  • Lexaria Bioscience (NASDAQ:LEXX) stock rose 11.18% to $3.66. The market value of their outstanding shares is at $6.5 million.
  • XORTX Therapeutics (NASDAQ:XRTX) stock increased by 10.84% to $1.84. The company's market cap stands at $3.2 million.
  • Senti Biosciences (NASDAQ:SNTI) stock moved upwards by 8.59% to $0.34. The market value of their outstanding shares is at $9.6 million.

Losers

  • Xenon Pharmaceuticals (NASDAQ:XENE) shares declined by 23.7% to $43.75 during Thursday's after-market session. The market value of their outstanding shares is at $5.4 billion.
  • Myriad Genetics (NASDAQ:MYGN) shares fell 9.32% to $3.75. The market value of their outstanding shares is at $364.5 million.
  • Exicure (NASDAQ:XCUR) stock decreased by 8.79% to $1.23. The company's market cap stands at $8.7 million.
  • Tessera Defense (AMEX:HLSQ) shares fell 5.0% to $0.65. The company's market cap stands at $1.9 million.
  • PepGen (NASDAQ:PEPG) shares decreased by 4.84% to $2.83. The company's market cap stands at $200.8 million.
  • CollPlant Biotechnologies (NASDAQ:CLGN) stock fell 4.25% to $3.88. The company's market cap stands at $6.5 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending